03 February 2020 : Laboratory Research
MiR-323-3p Targeting Transmembrane Protein with EGF-Like and 2 Follistatin Domain (TMEFF2) Inhibits Human Lung Cancer A549 Cell Apoptosis by Regulation of AKT and ERK Signaling PathwaysJi-min Fan1ACE, Zheng-rong Zheng2ACEF, Yi-Ming Zeng1BCF, Xiao-yang Chen1BCF*
Med Sci Monit 2020; 26:e919454
BACKGROUND: Non-small-cell lung cancer (NSCLC) is predominant and has low 5-year relative survival rate. Therefore, the mechanisms of NSCLC tumorigenesis must be comprehensively elucidated. MicroRNA-323-3p (miR-323-3p) has been widely explored and found to exert functions in tumorigenesis of several cancer types. However, the expression pattern and biological function of miR-323-3p and the molecular mechanism underlying NSCLC development and progression remain unclear.
MATERIAL AND METHODS: Quantitative reverse-transcription polymerase chain reaction was used to detect the expression of miR-323-3p and TMEFF2 in NSCLC cell lines (A549, NCI-H3255, and H1299) and normal cell line (BEAS-2B). Methylthiazolyl tetrazolium, colony formation, and flow cytometry assays were performed to evaluate the effects of miR-323-3p and TMEFF2 on cell proliferation. Transwell assay was conducted to determine the effects of TMEFF2 on cell migration and invasion. Dual-luciferase reporter assay was used to verify whether TMEFF2 is a target of miR-323-3p. Western blot analysis was performed to analyze protein expression.
RESULTS: The expression of miR-323-3p increased in the 3 NSCLC cell lines (A549, NCI-H3255, and H1299). miR-323-3p regulated cellular progression by directly suppressing TMEFF2 expression and indirectly prohibited the activation of AKT and ERK pathways in NSCLC.
CONCLUSIONS: Overall, miR-323-3p was considered a lung cancer oncogene and could be a valuable target for NSCLC therapy.
Keywords: Cellular Microenvironment, A549 cells, Down-Regulation, Gene Expression Regulation, Neoplastic, Membrane Proteins, Neoplasm Invasiveness, Neoplasm Proteins, Proto-Oncogene Proteins c-akt, Up-Regulation
01 January 2023 : EditorialEditorial: Current Status of Two Adjuvanted Malaria Vaccines and the World Health Organization (WHO) Strategy to Eradicate Malaria by 2030
Med Sci Monit 2023; 29:e939357
26 January 2023 : EditorialEditorial: The XBB.1.5 (‘Kraken’) Subvariant of Omicron SARS-CoV-2 and its Rapid Global Spread
Med Sci Monit In Press; DOI: 10.12659/MSM.939580
19 January 2023 : Clinical ResearchEvaluation of Health-Related Quality of Life and Mental Health in 729 Medical Students in Indonesia During ...
Med Sci Monit In Press; DOI: 10.12659/MSM.938892
19 January 2023 : Clinical ResearchDetermining the Impact of the COVID-19 Pandemic on Dental Care in the Serbian Adult Population: An Online Q...
Med Sci Monit 2023; 29:e939238
31 Jan 2023 : Clinical ResearchBalloon Dilation Eustachian Tuboplasty Combined with Tympanotomy Tube Insertion for Treatment of Refractory...
Med Sci Monit In Press; DOI: 10.12659/MSM.938879
31 Jan 2023 : Clinical ResearchComparison of Vision Correction and Corneal Thickness at 180-Day Follow-Up After Femtosecond Laser-Assisted...
Med Sci Monit In Press; DOI: 10.12659/MSM.939099
30 Jan 2023 : Clinical ResearchSplenic Artery Steal Syndrome in Patients with Liver Cirrhosis: A Retrospective Clinical Study
Med Sci Monit In Press; DOI: 10.12659/MSM.938998
Most Viewed Current Articles
13 Nov 2021 : Clinical ResearchAcceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical ResearchRetrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review articleA Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...
Med Sci Monit 2022; 28:e936292